{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"3.5","value":"2.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from randomization until first evidence of disease progression or death","dispersionType":"95% Confidence Interval","groups":[{"description":"Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.","id":"OG000","title":"Small Bowel Adenocarcinoma"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"3 years","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}